Hi Paul, the sp level, which you can't figure out why so low, is easy to be explained:
No deals at this stage, that's it. No deals mean no money, no confidence in the assets and no VALIDATION of any results achieved so far by big pharma.
Get deals done and the sp will move up, simple.
Even if IMU says the data so far are compelling, big pharma's hesitation tells holders anther story which is - not good enough to get involved.
Will that change? According to the "3 wise ones" today, yes. When? They want to beat 5 years to Azer-Cel approval which would be '28/'29/'30.
And that's the fastest / most progressed asset. Anything else like CF33 stand alone treatment or combo or onCARlytics will be, if ever approved, by mid 2030s.
At least they were honest today, no beating around the bush.
My investment strategy for IMU and CHM: trading when possible, to keep me up to date, but definitely no core investment due to the very long time frame, and raisings to come. Missing out on the first deal jump? Mmh, we all know that any jump will be crushed soon after, so hardly any missing out.
GLTA
IMU Price at posting:
2.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)